# US 11,027,012 B2 · Antigen binding proteins that bind PD-L1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,027,012 B2
- Document ID: US11027012B2
- Status: Granted
- Kind: B2
- Application number: 16/111,995
- Filed: 2018-08-24
- Published: 2019-02-28
- Granted: 2021-06-08
- Earliest claimed: 2012-05-31
- Assignees: Sorrento Therapeutics, Inc.
- Applicants: Sorrento Therapeutics, Inc.
- Inventors: Heyue Zhou; Randy Gastwirt; Barbara A. Swanson; John Dixon Gray; Gunnar F. Kaufmann
- Web page: https://patentgrep.com/patent/US11027012B2

## CPC

- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2121/00: Preparations for use in therapy
- C07K 2317/21: from primates, e.g. man
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.

## Claims

### Claim 1

A recombinant fully human anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in the heavy chain variable domain amino acid sequence of SEQ ID NO: 213; and comprising a light chain variable domain comprising CDRs as set forth in the light chain variable domain amino acid sequence of SEQ ID NO: 214.

### Claim 2 (depends on 1)

The anti-PD-L1 antibody of claim 1, wherein the antibody is an IgG.

### Claim 3 (depends on 1)

The anti-PD-L1 antibody, or antigen binding fragment thereof, of claim 1, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 213, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 214.

### Claim 4 (depends on 1)

The antigen binding fragment of the anti-PD-L1 antibody of claim 1, wherein the fragment is a Fab fragment.

### Claim 5 (depends on 1)

The antigen binding fragment of the anti-PD-L1 antibody of claim 1, wherein the fragment is a single chain human antibody.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the anti-PD-L1 antibody, or antigen-binding fragment thereof, of claim 1, and a pharmaceutically acceptable excipient.

### Claim 7 (depends on 1)

A method of treating a human subject having cancer comprising administering an effective amount of the anti-PD-L1 antibody, or antigen binding fragment thereof, of claim 1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cancer is selected from the group consisting of ovarian cancer, colon cancer, breast cancer, lung cancer, myeloma, a neuroblastic-derived CNS tumor, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, a B-cell derived lymphoma, a T-cell derived lymphoma, skin cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck cancer, pancreatic cancer, bladder cancer, bone cancer, cartilage cancer, liver cancer, lymph node cancer, nervous tissue cancer, skeletal muscle cancer, spinal cord cancer, spleen cancer, brain cancer, colorectal cancer, thyroid cancer, prostate cancer, vaginal cancer, kidney cancer, thymus cancer, thyroid cancer, stomach cancer, cancer of the urogenital tract, cancer of the ureter, cancer of the urethra, cancer of the uterus, cancer of the testes, and a mast cell derived tumor.

### Claim 9 (depends on 4)

A method for treating a human subject having cancer, said method comprising administering an effective amount of the fully human antibody Fab fragment of claim 4 to the human subject.

### Claim 10 (depends on 5)

A method for treating a human subject having cancer, said method comprising administering an effective amount of the single chain human antibody of claim 5 to the human subject.